[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Soonchunhyang University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":211},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,82,107,131,159,185],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100638664","comparison-of-a-short-modified-metal-stent-versus-plastic-stent-as-a-bridge-to-surgery-in-pancreatic-cancer-with-malignant-biliary-obstruction-100638664",false,"NCT07606430","Comparison of a Short Modified Metal Stent Versus Plastic Stent as a Bridge to Surgery in Pancreatic Cancer With Malignant Biliary Obstruction","Multicenter Randomized Trial of a Short Modified 8-mm-diameter Fully Covered Metal Stent Versus Plastic Stent as a Bridge to Surgery in Pancreatic Cancer With Malignant Biliary Obstruction","BRIDGE-8","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Patients with resectable, borderline resectable, or locally advanced pancreatic cancer with distal malignant biliary obstruction requiring endoscopic biliary drainage\n3. Biliary stricture located ≥ 2 cm below the hepatic hilum\n4. Serum bilirubin ≥ 3 mg\u002FdL\n5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n6. Ability to provide written informed consent\n\nExclusion Criteria:\n\n1. Presence of distant metastasis\n2. Prior biliary stent placement for biliary obstruction\n3. Requirement for duodenal stent placement due to gastric outlet obstruction\n4. Estimated life expectancy \\\u003C 3 months\n5. Inability to undergo ERCP\n6. Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study outcomes","ALL","18 Years",{"count":20,"type":21},116,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is a multicenter, randomized clinical trial designed to compare the effectiveness and safety of a modified 8-mm fully covered self-expandable metal stent (FCSEMS) with a conventional plastic stent for preoperative biliary drainage in patients with pancreatic cancer and malignant biliary obstruction.\n\nIn patients who require biliary drainage before surgery, stent placement is commonly performed using endoscopic retrograde cholangiopancreatography (ERCP). However, the optimal stent type remains uncertain.\n\nParticipants will be randomly assigned to receive either the modified FCSEMS or a plastic stent. The primary objective is to evaluate the rate of stent-related complications requiring reintervention before surgery. Secondary outcomes include stent patency, adverse events, and surgical outcomes.\n\nThe results of this study are expected to help determine the most appropriate stent strategy for patients undergoing surgery for pancreatic cancer.",[27,28],"Pancreatic Cancer","Malignant Biliary Obstruction",[30,31,32,33,34,35],"pancreatic cancer","malignant biliary obstruction","preoperative biliary drainage","ERCP","fully covered self-expandable metal stent","plastic stent","NOT_YET_RECRUITING","2026-05-18",{"date":39,"type":40},"2026-05-26","ACTUAL",{"date":42,"type":21},"2026-05-01",{"date":44,"type":21},"2029-12-31",{"name":46,"class":47},"Soonchunhyang University Hospital","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100630510","phase-3-progain-trial-in-gastric-cancer-surgery-100630510","NCT07488611","PROGAIN Trial in Gastric Cancer Surgery","The PROGAIN Trial : A Randomized Study of Protein-enriched Parenteral Nutrition on Nitrogen Balance and Recovery in Perioperative Gastric Cancer Surgery","PROGAIN","Inclusion Criteria:\n\n* Adults aged 19 years or older scheduled to undergo gastric cancer surgery. - Patients who have provided written informed consent to participate in this study.\n\nExclusion Criteria:\n\n* Patients with uncontrolled severe systemic diseases (e.g., decompensated diabetes, cerebrovascular event within the last 6 months, sepsis, heart failure).\n* Patients who have received intravenous parenteral nutrition within 7 days prior to randomization.\n* Patients with severe metabolic abnormalities confirmed by preoperative laboratory tests, including but not limited to:\n\n  * Triglyceride \\> 400 mg\u002FdL\n  * AST or ALT \\> 3 x Upper Limit of Normal (ULN)\n  * Total Bilirubin \\> 3 x ULN\n  * Serum Creatinine \\> 2 x ULN\n  * HbA1c \\> 9.0%\n  * Potassium \\\u003C 3.0 mEq\u002FL or \\> 6.0 mEq\u002FL\n  * Calcium \\> 12.5 mg\u002FdL\n  * Sodium \\> 155 mmol\u002FL\n  * Magnesium \\> 3.0 mg\u002FdL\n* Patients deemed inappropriate for participation in this clinical trial by the investigator.","19 Years",{"count":58,"type":21},110,[60],"PHASE3","This randomized study will evaluate whether protein-enriched parenteral nutrition improves early postoperative recovery in patients undergoing gastrectomy for gastric cancer. Participants will be assigned to receive either protein-enriched parenteral nutrition or standard parenteral nutrition during the perioperative period. The primary outcome is nitrogen balance on postoperative day 5. Secondary outcomes include postoperative complications, recovery of oral intake, and short-term changes in nutritional status and body composition.",[63],"Stomach (Gastric) Cancer",[65,66,67,68,69,70,71],"Parenteral Nutrition","Gastrectomy","Nitrogen Balance","Protein enriched","Perioperative nutrition","Enhanced Recovery After Surgery","Stomach Neoplasms","RECRUITING","2026-05-16",{"date":75,"type":40},"2026-05-19",{"date":77,"type":40},"2026-02-13",{"date":79,"type":21},"2028-03",{"name":46,"class":47},1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":5},"100526980","twice-vs-thrice-weekly-incident-hemodialysis-in-elderly-patients-100526980","NCT06141798","Twice vs Thrice Weekly Incident Hemodialysis in Elderly Patients","A Pragmatic Randomized Clinical Trial: Twice-weekly vs Thrice-weekly Incident hemoDialysis in Elderly Patients","Inclusion Criteria:\n\n* Age ≥60 years\n* Clinical diagnosis of end stage kidney disease\n* Starting maintenance hemodialysis within one month\n* 24-hour urine output ≥ 500 ml at randomization\n* Sufficient understanding of the study procedures and requirements.\n\nExclusion Criteria:\n\n* Left ventricular ejection fraction \\\u003C 40%)\n* Liver cirrhosis\n* Current treatment for an active malignancy or active infection\n* Onability or refusal to provide written informed consent\n* enrollment in another clinical trial.","60 Years",{"count":91,"type":21},428,[24],"As Korea is becoming a super-aged society, the number of elderly patients with end-stage kidney disease (ESKD) is expected to increase rapidly. Therefore, the burden on Korean society will also increase.\n\nThrice-weekly hemodialysis is standard for renal replacement therapy. However, this regimen has not been validated for elderly ESKD patients with residual renal function. Elderly patients can have multiple comorbidities such as hypertension, diabetes, cardiovascular disease, and impaired physical activity. Frequent hemodialysis could provoke falls, hypotension, and cognitive impairment. Previous reports have suggested the potential benefit of twice-weekly hemodialysis with incremental increases in frequency when residual renal function decreases. In addition, twice-weekly hemodialysis decreases hospitalization rates in frail patients.\n\nTherefore, the investigators hypothesized initiating renal replacement therapy with twice-weekly hemodialysis decreases the hopsitalizatoin rates compared with conventional thrice-weekly hemodialysis in elderly ESRD patients with residual renal function. This study is a pragmatic randomized clinical trial, multicenter study. Study subjects are incident ESRD patients (\\>= 60 years old, n=428) with residual urine volume ( \\> 500 mL\u002Fday) and follow up up to 2 years. Twice-weekly hemodialysis could be incremented according to clinical situations such as volume overload, hyperkalemia and uremic symptom. Primary outcome of this study is hospitalization rate during follow-up. Secondary outcomes include dialysis related hospitalization rate, the length of hospital stay, complication of dialysis,mortality rate and assessments of quality of life, frailty, and cost-utility.",[95,96,97,98],"Age Problem","Dialysis; Complications","Frailty","Quality of Life","2026-05-06",{"date":101,"type":40},"2026-05-11",{"date":103,"type":40},"2021-11-23",{"date":105,"type":21},"2026-05-31",{"name":46,"class":47},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":118,"studyType":119,"phases":4,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":81},"100568538","tegoprazan--versus-ppi-based-h-pylori-eradication-100568538","NCT06682533","Tegoprazan- Versus PPI-based H. Pylori Eradication","Efficacy and Tolerability of 14-Day Tegoprazan-based Triple Therapy for Eradication of Helicobacter Pylori Eradication: A Retrospective Study","Inclusion Criteria:\n\n* Gastroscopy can be performed\n* H. pylori test and pathological analysis can be performed\n\nExclusion Criteria:\n\n* Age \\\u003C 20 or \\> 80 years\n* Anemia (serum hemoglobin level \\\u003C 10 g\u002FdL)\n* Severe systemic disease\n* Advanced chronic liver disease\n* Use of certain medications, including proton pump inhibitors, H2- receptor antagonists, or antibiotics\n* History of H. pylori eradication\n* Drug allergy to antibiotics\n* History of gastric surgery\n* Recent history of upper gastrointestinal bleeding","20 Years","80 Years",{"count":117,"type":21},200,"1 Year","OBSERVATIONAL","In 2015, vonoprazan, a potassium-competitive blocker (P-CAB), was launched in Japan and used as an alternative for proton pump inhibitors (PPIs) for eradicating Helicobacter pylori. In recent studies, vonoprazan-based triple therapy significantly increased the eradication rate from 72.8% to 87.9%, compared to PPI treatment group. Accordingly, the Japanese Helicobacter treatment guidelines recommend prescribing P-CAB for eradication treatment. In 2018, a new P-CAB, tegoprazan, was developed in Korea and approved for gastric ulcer treatment. Subsequently, it was proven effective in the treatment of reflux esophagitis compared to PPIs in a non-inferiority clinical trial. P-CAB can increase the gastric pH to 6 or higher within 7 hours after taking tegoprazan. Because tegoprazan can be taken after meals, it can improve patient compliance for H. pylori eradication. Unlike vonoprazan in Japan, however, tegoprazan-based eradication in Korean population was similar to conventional PPI-based treatment. To date, the eradication success rates of PPI and tegoprazan-based triple therapy were 76.4-84.2% and 77.3-84.3%, respectively, and there was no significant difference between the two treatment groups.\n\nBismuth has long been used as a semi-metal in the dyspepsia and traveler's diarrhea. In H. pylori eradication therapy, several guidelines recommended the addition of bismuth to treatment regimens. Recently, bismuth was added to the 2-week triple regimen to increase the first-line H. pylori eradication rate in countries with high antibiotic resistance. The H. pylori eradication significantly increased from 87.5-88.1% to 95.8-97.3% in a recent study. The odds ratio was 1.63-2.18 in bismuth-added treatment group, compared to no use of bismuth group. In subgroup analysis, odd ratio was 1.66-2.22 in high clarithromycin-resistant areas. However, there was no comparative analysis of PPIs and tegoprazan in a bismuth-added triple therapy.",[122],"H.Pylori Infection","2026-04-21",{"date":125,"type":40},"2026-04-23",{"date":127,"type":40},"2024-12-01",{"date":129,"type":21},"2026-12-31",{"name":46,"class":47},{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":138,"sex":17,"minAge":18,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":147,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":4},"100609362","virtual-reality-treatment-for-trauma-related-to-covid-19-infection-100609362","NCT07213596","Virtual Reality Treatment for Trauma Related to COVID-19 Infection","Development of Virtual Reality Treatment Technology to Treat Trauma Related to COVID-19 Infection","Inclusion Criteria:\n\n* Age 18-64, healthy population who survived from COVID-19 (COVID survivors) or Healthcare Workers with PCL-5 ≥10, GAD-7\u002FPHQ-9 ≥10\n\nExclusion Criteria:\n\n* Pregnancy, neurological disorders, severe medical conditions",true,"64 Years",{"count":141,"type":21},100,[24],"This clinical trial aims to develop and evaluate the effectiveness of virtual reality (VR)-based exposure therapy for trauma symptoms related to COVID-19 infection. The intervention targets healthcare workers and individuals from the general population who experienced pandemic-related psychological distress. The study assesses psychological and physiological outcomes, including PTSD, anxiety, depression, HRV, and EEG biomarkers.",[145,146],"PTSD","PTSD Symptoms",[148,149,150],"VR exposure","PTSD symptoms","covid 19","2025-10-01",{"date":153,"type":40},"2025-10-09",{"date":155,"type":21},"2025-11-01",{"date":157,"type":21},"2027-07-31",{"name":46,"class":47},{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":170,"conditions":171,"keywords":174,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":184},"100495588","abscopal-effect-from-the-low-dose-radiotherapy-in-polymetastatic-cancer-patients-receiving-stereotactic-radiotherapy-100495588","NCT05733156","Abscopal Effect from the Low-dose Radiotherapy in Polymetastatic Cancer Patients Receiving Stereotactic Radiotherapy","Abscopal Effect from the Addition of Low-dose Radiotherapy in Polymetastatic Cancer Patients Receiving Stereotactic Radiotherapy: a Multicenter, Single-arm Clinical Study (KROG 22-11)","KROG22-11","Inclusion Criteria:\n\n* Patients who can provide their written informed consent\n* Age ≥19 years\n* Patients with histologically confirmed primary solid (irrespective of the status of the primary tumor)\n* Patients with ECOG performance status 0-2\n* Patients planning stereotactic body radiotherapy (three fractions) for extracranial metastases\n* Based on RECIST v1.1, patients with at least one extracranial measurable lesion other than SBRT lesions\n* Patients with one or more measurable lesions, which are not suitable for SBRT or palliative radiotherapy and can be considered for LDRT (bone metastasis is not indicated for LDRT)\n* Patients with hematologic function suitable for radiotherapy (absolute neutrophil count ≥1,500\u002Fmm\\^3, hemoglobin ≥9 g\u002FdL, platelet count ≥100,000\u002Fmm\\^3)\n* Patients with a life expectancy of 6 months or more according to the researcher's judgment\n\nExclusion Criteria:\n\n* Patients participating in other clinical studies that may affect the efficacy\u002Fsafety of this clinical study\n* Patients with brain metastasis\n* Patients planning SBRT for all measurable lesions due to oligometastasis\n* Patients with a history of radiotherapy for extracranial metastases within 3 months of the enrollment\n* Patients unable to cooperate with stereotactic body radiotherapy\n* Patients who are pregnant or planning to\n* Patients with advanced or multiple malignancies requiring aggressive treatment (excluding skin cancers other than melanoma or intraepithelial cancer)\n* Patients who have received systemic steroid therapy or immunosuppressive therapy within 2 weeks of enrollment - Patients with an (e.g. allergic disease, radiation pneumonitis, etc.) (The use of steroids for preventive purposes is allowed (e.g., to prevent vomiting during chemotherapy)) active autoimmune disease requiring systemic treatment within the past 2 years, evidence of clinically severe autoimmune disease, or syndrome requiring systemic steroid or immunosuppressive therapy (Patients who need intermittent use of bronchodilators, inhaled steroids, or topical steroid injections, hypothyroid patients on stable hormone replacement therapy, type 1 diabetes patients, or patients recovering from childhood asthma\u002Fatopic dermatitis are permitted)\n* Patients with active infection requiring systemic treatment",{"count":168,"type":21},52,[24],"Recently, MD Anderson Cancer Center reported the phase II trial to investigate high-dose radiotherapy (HDRT, 20-70 Gy) and low-dose radiotherapy (LDRT, 1-10 Gy) for metastatic cancer patients who had undergone immunotherapy. HDRT or HDRT+LDRT was conducted in two respective groups and the treatment group was determined according to the disease status of participants, not randomization. Immunotherapy was maintained in this clinical study. Therefore, we aim to investigate this abscopal effect from adding LDRT to HDRT, irrespective of previous immunotherapy, in this multicenter, single-arm study.",[172,173],"Neoplasms","Secondary Malignant Neoplasm",[175],"Neoplasm Metastasis","2024-12-05",{"date":178,"type":40},"2024-12-10",{"date":180,"type":40},"2023-01-03",{"date":182,"type":21},"2026-06",{"name":46,"class":47},2,{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":115,"enrollmentInfo":193,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":195,"conditions":196,"keywords":199,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":4},"100544516","digital-single-operator-cholangioscopy-and-intraductal-ultrasound-for-nonicteric-biliary-strictures-100544516","NCT06369896","Digital Single-operator Cholangioscopy and Intraductal Ultrasound for Nonicteric Biliary Strictures","The Usefulness of Disposable Digital Single-operator Cholangioscopy and Intraductal Ultrasound in the Assessment of Nonicteric Biliary Strictures: A Prospective Observational Study","Spy+IDUS","Inclusion Criteria:\n\n1. Patients aged 19 to under 80\n2. Presence of nonicteric biliary stricture\n3. Previous endoscopic sphincterotomy or papillary balloon dilatation\n\nExclusion Criteria:\n\n1. Bleeding tendency (INR \\> 1.5 or platelets \\< 50000 mm3)\n2. Contraindication to ERCP",{"count":194,"type":21},36,"This study aims to evaluate the usefulness of disposable digital single-operator cholangioscopy (SOC) and intraductal ultrasound (IDUS) for the accurate diagnosis of indeterminate biliary stricture.",[197,198],"Cholangiocarcinoma","Biliary Stricture",[200,201,202],"intraductal ultrasound","digital single-operator cholangioscopy","indeterminate biliary stricture","2024-04-16",{"date":205,"type":40},"2024-04-17",{"date":207,"type":21},"2024-05-05",{"date":209,"type":21},"2026-12-25",{"name":46,"class":47},""]